Unravel announces rareSHIFT™

rareSHIFT™ provides industry and foundations access to Unravel’s drug discovery engine to accelerate patient-centered drug development. Unravel Biosciences, Inc., (“Unravel”), a therapeutics company leveraging a machine-learning model of human health to advance drugs for complex diseases, today announced the release of a groundbreaking new initiative, rareSHIFT™, to facilitate patient-centric drug...

The post Unravel announces rareSHIFT™ first appeared on AI-TechPark.

advance development discovery diseases drug development drug discovery drugs groundbreaking health human industry machine machine learning patient release therapeutics